OncoResponse Appoints Carol Gallagher, Pharm.D., as Independent Director to Board of Directors

OncoResponse, a notable clinical-stage biotech startup at the forefront of immunotherapy research, has expanded its leadership team significantly. Carol Gallagher, Pharm.D., was appointed as an Independent Director to the company's Board of Directors on September 6, 2023.

Dr. Carol brings with her almost three decades of expertise in the pharmaceutical sector. Her knowledge in drug research, business development, and commercial operations makes her an invaluable contributor to OncoResponse's aim of advancing cancer discovery and development through cutting-edge immunotherapies.

Dr. Carol now serves on many private and public boards and is a venture adviser at New Enterprise Associates (NEA), a well-known venture capital company. Her diverse background qualifies her as a strategic leader capable of using her clinical and commercial expertise, as well as her financial insights, to deliver vital guidance to both public and private firms.

"Carol is a highly regarded industry leader with a broad array of expertise that will be invaluable to OncoResponse as we advance our leading cancer discovery and development efforts," said Clifford Stocks, OncoResponse's Chief Executive Officer. "Carol excels at leveraging her clinical and commercial expertise, as well as financial insights, to provide strategic direction to both public and private companies." We are excited to have her as a member of our Board."

Dr. Carol has been involved with New Enterprise Associates since 2014, and she is a member of the Salk Institute's Board of Trustees. She is the head of the Salk Women & Science Advisory Committee of the Salk Institute. Dr. Gallagher also serves on the boards of many public firms, including Mirati Therapeutics, PMV Pharma, and Atara Biotherapeutics, as well as several private, venture-backed companies.

Her significant career highlights include serving as President and CEO of Calistoga from 2008 to 2011, a business that was ultimately bought by Gilead Sciences. Prior to joining Calistoga, she worked at a number of well-known pharmaceutical businesses, including Amgen, Agouron Pharmaceuticals, Pfizer, IDEC Pharmaceuticals, CancerVax, Anadys, and Eli Lilly.

"I'm thrilled to be joining the Board of Directors at OncoResponse and look forward to working with the team to achieve new breakthroughs in immunotherapy," Dr. Carol stated. "The company's expanding pipeline of macrophage-modulating antibodies presents an enticing opportunity to use the immune system to fight cancer."

With the appointment of Dr. Carol to its Board of Directors, OncoResponse strengthens its commitment to developing innovative immunotherapies derived from the immune systems of Elite Cancer Responders and cements its position as a pioneer in cancer research.